Brief: Bioinvent Submits CTA For Phase 1/2A Trial Of Bi-1607, Novel Anti-FcyRIIB Antibody

BioInvent International AB

08/12/2021 07:04

Dec 8 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT HAS SUBMITTED A CTA FOR A PHASE 1/2A TRIAL OF
BI-1607,
A NOVEL ANTI-FCYRIIB ANTIBODY FOR THE TREATMENT OF PATIENTS WITH
SOLID TUMORS
    * TO EXPLORE ACTIVITY OF BI-1607 IN ADVANCED SOLID TUMORS
AND
ANTIBODY COMBINATIONS SUPPORTED BY STRONG PRECLINICAL DATA.

Source text for Eikon:  ID:nMFN2ndZPv 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))